As many as 2 million people have been exposed to carcinogens in several generic blood pressure drugs; flu activity has worsened over the past week; and real-world data is changing how researchers study drug efficacy and safety.
The FDA has warned that as many as 2 million people worldwide could have been exposed to probable human carcinogens in a class of generic blood pressure medications, and at least half of these people taking the medications are in the United States. According to The Wall Street Journal, the contaminated drugs include valsartan, irbesartan, and losartan. However, the band name versions of these medications are not affected, nor are all generic products.Since October, there have been approximately 11.4 million 5.4 million doctor visits, and 136,000 flu hospitalizations, reported CNN. While this flu season is poised to be milder than last, flu activity has worsened over the past week, with an additional 3 children dying due to flu-related causes. There have been a total of 22 flu-related deaths this season.
The use of real-world evidence is changing how researchers determine the safety and efficacy of drugs. When drugs are used in clinical practice following trials and FDA approval, they are often used in settings different from those studied in the trials. According to STAT News, it’s time for biotech and pharmaceutical companies to pay more attention to and understand real-world studies, a position that has been backed by FDA Commissioner Scott Gottlieb, MD.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More